NCT00617370 - Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

July 31, 2005

Study Completion Date

June 30, 2008

Conditions

Breast CancerAdenocarcinoma of the Breast

Interventions

DRUG

epirubicin, cyclophosphamide, Paclitaxel,

EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg). Paclitaxel (175 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg).

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York